Posted by Michael Wonder on 19 May 2022
G-BA certifies active ingredients against breast and oesophageal cancer as having a high additional benefit
19 May 2022 - The Federal Joint Committee (G-BA) has rated the patient-relevant additional benefit of two active ingredients for cancer therapy as high compared to previous therapy standards:
Sacituzumab govitecan, which is used as a monotherapy against a special form of breast cancer in a is used in a very advanced stage of the disease, the longer survival time combined with an improved quality of life for those affected was an important effect.
Nivolumab – combined with chemotherapy – which has been evaluated in advanced oesophageal or gastric cancer, also shows a significant improvement in overall survival, at least in some of those affected.
